IRIS
MENNA, PIERANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.216
NA - Nord America 727
EU - Europa 387
SA - Sud America 81
AF - Africa 17
OC - Oceania 12
Totale 5.440
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.337
US - Stati Uniti d'America 678
CN - Cina 478
HK - Hong Kong 297
GB - Regno Unito 102
DE - Germania 78
BR - Brasile 62
CZ - Repubblica Ceca 54
IT - Italia 50
VN - Vietnam 27
FI - Finlandia 25
IN - India 25
CA - Canada 23
MX - Messico 20
NL - Olanda 18
AU - Australia 12
ZA - Sudafrica 10
PL - Polonia 9
AR - Argentina 8
JP - Giappone 8
BD - Bangladesh 7
FR - Francia 7
ID - Indonesia 7
UA - Ucraina 7
BE - Belgio 6
TR - Turchia 5
PT - Portogallo 4
TW - Taiwan 4
AL - Albania 3
AT - Austria 3
CL - Cile 3
EE - Estonia 3
ES - Italia 3
LT - Lituania 3
PY - Paraguay 3
SE - Svezia 3
AE - Emirati Arabi Uniti 2
CO - Colombia 2
DO - Repubblica Dominicana 2
EC - Ecuador 2
GE - Georgia 2
IE - Irlanda 2
IQ - Iraq 2
PH - Filippine 2
PK - Pakistan 2
RU - Federazione Russa 2
TN - Tunisia 2
UZ - Uzbekistan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CR - Costa Rica 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
GA - Gabon 1
IL - Israele 1
JO - Giordania 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MR - Mauritania 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
VE - Venezuela 1
YE - Yemen 1
Totale 5.440
Salva come PNG Salva come JPEG
Città #
Singapore 310
Hong Kong 295
Hefei 183
Ashburn 152
Boardman 106
Beijing 99
London 82
Dallas 63
Shanghai 59
Munich 48
Brno 35
Los Angeles 34
Council Bluffs 27
Rome 26
San Francisco 26
Redmond 20
Pune 18
Amsterdam 17
Olomouc 17
Mexico City 16
Turku 14
Seattle 13
Guangzhou 11
Helsinki 11
Santa Clara 11
São Paulo 11
Washington 11
Ho Chi Minh City 10
New York 10
Toronto 10
Boston 9
Manchester 8
Brooklyn 7
Hanoi 7
Tokyo 7
Warsaw 7
Melbourne 6
Chicago 5
Atlanta 4
Haikou 4
Johannesburg 4
Montreal 4
Ankara 3
Canberra 3
Chennai 3
Dhaka 3
Hangzhou 3
Hanover 3
Mol 3
Oklahoma City 3
Paris 3
Stockholm 3
Sydney 3
Taipei 3
Tirana 3
Wuhan 3
Aversa 2
Bismarck 2
Biên Hòa 2
Buenos Aires 2
Campinas 2
Colombo 2
Concord 2
Curitiba 2
Dublin 2
Florence 2
Genoa 2
Grand Rapids 2
Haiphong 2
Hasselt 2
Iowa City 2
Lodz 2
Luoyang 2
New Delhi 2
North Liberty 2
Nuremberg 2
Palermo 2
Phoenix 2
Porto 2
Quito 2
Rio de Janeiro 2
Shanwei 2
Shenzhen 2
Tallinn 2
Tashkent 2
Tbilisi 2
The Dalles 2
Topeka 2
Vilnius 2
West Jordan 2
Xi'an 2
Xiamen 2
Zhengzhou 2
Alcobaça 1
Alfenas 1
Almaty 1
Amman 1
Ansan-si 1
Apizaco 1
Asunción 1
Totale 1.940
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 204
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 186
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 185
Cancer drugs and QT prolongation: weighing risk against benefit 184
Minimal sampling colistin pharmacokinetics in critically ill patients 183
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 177
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 174
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 171
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 170
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 170
Cardio-oncology in clinical studies and real life 168
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 162
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 154
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 138
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 123
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 106
Anthracyclines 105
Anthracycline Cardiotoxicity 104
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 100
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 98
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 97
Anthracycline Cardiotoxicity 89
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 84
An introduction to the metabolic determinants of anthracycline cardiotoxicity 79
Cardiotoxicity of antitumor drugs 74
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 69
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 67
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 63
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 51
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 50
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 50
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 47
Pharmacology of Cardio-Oncology 47
What is cardiotoxicity? 44
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 41
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 39
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 39
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 37
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 37
Isavuconazole: case report and pharmacokinetic considerations 37
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 37
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 35
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 35
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 34
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 34
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 34
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 34
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 33
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 33
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 33
Matters of the heart: The case of TNF-alpha targeting drugs 31
The concomitant management of cancer therapy and cardiac therapy 31
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 30
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 29
Molecular determinants of the reduced cardiotoxicity of epirubicin 28
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples 27
Pharmacological Foundation of Cardio-Oncology 27
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 27
MEN 10755 : A novel disaccharide anthracycline with a reduced level of formation and [4Fe-4S]-reactivity of toxic alcohol metabolite in human heart . 27
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 26
MEN 10755: a novel disaccaride anthracycline with a reduced level of formation and [4Fe-4S]- reactivity of toxic alcohol metabolite in human myocardium 26
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 26
Quantitative Analysis of Cenobamate and Concomitant Anti-Seizure Medications in Human Plasma via Ultra-High Performance Liquid Chromatography–Tandem Mass Spectrometry 26
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 25
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 25
Doxorubicin degradation in cardiomyocytes 24
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 24
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 24
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 24
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 24
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 23
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 22
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 22
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 22
Translating molecular mechanisms into clinical facts 22
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 22
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 22
Humans and Rodents: The Case of hOAT4 and mOat5 21
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 21
In ®Entresto we trust 21
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 21
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 21
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 20
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 20
Recommendations for the harmonization of reference intervals in the therapeutic monitoring of antiepileptic drugs/Indicazioni per l’armonizzazione degli intervalli di riferimento nel monitoraggio terapeutico di farmaci antiepilettici 19
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: relative importance of vesicular sequestration and impaired efficiency of electron addition J. Biol. Chem 19
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 19
Do you know pixantrone? 18
The reality of pixantrone in real life 17
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 17
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 17
Correction: Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 16
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 14
Cenobamate modulates EEG cortical activity and connectivity in individuals with drug-resistant epilepsy: a pharmaco-EEG study 9
Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) 3
Totale 5.544
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022218 0 4 0 0 0 0 1 92 4 0 5 112
2022/202356 2 1 1 4 2 2 15 0 3 3 22 1
2023/2024333 6 35 11 15 37 146 1 16 2 8 4 52
2024/20254.043 102 36 123 15 45 77 40 21 250 263 1.446 1.625
2025/2026894 336 204 131 223 0 0 0 0 0 0 0 0
Totale 5.544